Your browser doesn't support javascript.
loading
Molecular antimicrobial susceptibility testing in sepsis.
Martin-Loeches, Ignacio; Pereira, João Gonçalves; Teoh, Tee Keat; Barlow, Gavin; Dortet, Laurent; Carrol, Enitan D; Olgemöller, Ulrike; Boyd, Sara E; Textoris, Julien.
Affiliation
  • Martin-Loeches I; Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James' Hospital, D08 NHY1, Dublin, Ireland.
  • Pereira JG; Hospital Clinic, Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Ciberes, 08036 Barcelona, Spain.
  • Teoh TK; Hospital Vila Franca de Xira, Portugal.
  • Barlow G; Faculdade de Medicina da Universidade de Lisboa.
  • Dortet L; Department of Clinical Microbiology, St James' Hospital, Dublin, Ireland.
  • Carrol ED; York Biomedical Research Institute, University of York and Hull York Medical School, UK.
  • Olgemöller U; Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • Boyd SE; Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
  • Textoris J; INSERM UMR 1184, RESIST Unit, Paris-Saclay University, Le Kremlin-Bicêtre, France.
Future Microbiol ; 19: 61-72, 2024 01.
Article in En | MEDLINE | ID: mdl-38180334
ABSTRACT
Rapidly detecting and identifying pathogens is crucial for appropriate antimicrobial therapy in patients with sepsis. Conventional diagnostic methods have been a great asset to medicine, though they are time consuming and labor intensive. This work will enable healthcare professionals to understand the bacterial community better and enhance their diagnostic capacity by using novel molecular methods that make obtaining quicker, more precise results possible. The authors discuss and critically assess the merits and drawbacks of molecular testing and the added value of these tests, including the shift turnaround time, the implication for clinicians' decisions, gaps in knowledge, future research directions and novel insights or innovations. The field of antimicrobial molecular testing has seen several novel insights and innovations to improve the diagnosis and management of infectious diseases.
Sepsis is a life-threatening reaction to an infection. This infection is normally caused by a bacteria. Identifying the bacteria that has caused the infection is very important to choosing the best treatment. This is usually done using molecular testing. This article discusses the advantages and disadvantages of molecular testing, which tests are available and the value of these tests in clinical practice, the implication of molecular tests for clinicians' decisions and the gaps in our knowledge. It also discusses future innovations in molecular testing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sepsis / Anti-Infective Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Future Microbiol Journal subject: MICROBIOLOGIA Year: 2024 Document type: Article Affiliation country: Ireland Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sepsis / Anti-Infective Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Future Microbiol Journal subject: MICROBIOLOGIA Year: 2024 Document type: Article Affiliation country: Ireland Country of publication: United kingdom